Clinical Trial Update: The ASCEND Study: Gemcitabine and Nab-Paclitaxel With LSTA1 (Certepetide) or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 ASCEND trial evaluating gemcitabine and nab-paclitaxel with LSTA1 (certepetide) versus placebo in untreated metastatic pancreatic ductal adenocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• LSTA1 (certepetide) (certepetide)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Australasian Gastro-Intestinal Trials Group | Conditions: Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING